Aier Eye Hospital Investment Quality Review (300015.SZ)

Quality score: 80/100 Valuation position: current price/base FV 1.37 Final signal: WATCHLIST

Core Conclusion

Aier Eye Hospital is WATCHLIST. Current price is CNY8.62, above conservative/base FV of CNY3.62/CNY6.30. The business quality is good, but valuation and balance-sheet pressure block a BUY signal.

Business And Quality

Five-year revenue CAGR is 10.5% and latest-year FCF is CNY3.88bn. The 80/100 score reflects growth and cash generation, while healthcare execution, acquisition risk, and net debt limit confidence.

Financial Audit

The review uses fiscal 2021-2025 in CNY. Five-year average FCF/Net Income is 1.14 and OCF/Net Income is 1.69. Latest net debt is CNY1.92bn. Market value is about CNY80.16bn on roughly 9.300bn shares.

Valuation

The valuation uses normalized FCF, a 1.7% CNY 10Y yield dated 2026-07-27, and separate balance-sheet adjustments. Price/base FV of 1.37 gives no margin of safety, and conservative FV is far below current price.

Buy And Monitor

Current action is watchlist. Upgrade requires price/base FV below 0.70, quality score at least 75, and stronger evidence that growth and FCF are durable. Track revenue trend, FCF/Net Income, ROIC, net debt, dividends, buybacks, and governance disclosure.

Risks

Risks include acquisition integration, medical-service regulation, weaker FCF conversion, leverage, and governance or incentive dilution. Two periods with FCF/Net Income below 0.60 would require lower normalized FCF.

Sources

Sources are public quote and financial data platforms, official filings or company IR, and ChinaBond for the CNY risk-free rate. Research only, not personalized investment advice.